Non disponible en dehors du Royaume-Uni et de l'Irlande

Application

5,6-Dichlorobenzimidazole 1-β-D-ribofuranoside has been used:as an inhibitor of RNA polymerase II in mouse melanoma cellsfor the inhibition of cyclin D1 mRNA synthesis in human prostate epithelial cell linesin the inhibition of interleukin-2 gene transcription in Jurkat cells

Biochem/physiol Actions

Inhibitor of RNA synthesis; causes premature termination of transcription. CK2 (casein kinase-2) inhibitor.

5,6-Dichlorobenzimidazole 1-β-D-ribofuranoside (DRB), a nucleoside analog that halts mRNA synthesis by phosphorylation of the C-terminal domain of RNA polymerase II, making it inactive. It also interferes with the DNA topoisomerase II, may modulate response to cytokines and blocks the human immunodeficiency virus (HIV) via RNA modification. It also inhibits cyclin-dependent kinases (CDKs) 7 and 9 and favors apoptosis in leukemic cells. It may serve as a therapeutic agent in treating cancer.

Features and Benefits

This compound is a featured product for Gene Regulation research. Click here to discover more featured Gene Regulation products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

Packaging

50 mg in glass bottle

10 mg in poly bottle